Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18672091 | 0.88 | POLG (0.51) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL16144277 | 0.88 | POLG (0.51) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL17863916 | 0.88 | POLG (0.49) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL17458663 | 0.88 | POLG (0.49) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL17359383 | 0.88 | POLG (0.49) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL15070576 | 0.88 | POLG (0.49) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL15074337 | 0.88 | POLG (0.49) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL15074336 | 0.87 | POLG (0.53) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL26272358 | 0.87 | POLG (0.53) | POLGP2RY2POLBP2RY4P2RY6 | |
| SCHEMBL19590336 | 0.87 | P2RY2 (0.50) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | POLG 40/4885P2RY2 3763/4885POLB 16/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | POLG 40/4885P2RY2 3763/4885POLB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.